

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) One or more chemical entities selected from 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepinium maleate and a pharmaceutically acceptable solvate thereof.
2. (Original) One or more chemical entities selected from 7-[4-(4-chlorobenzoyloxy)-benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepinium tosylate and a pharmaceutically acceptable solvate thereof.
3. (Original) A chemical entity according to claim 1 wherein the ratio of 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine to maleic acid (by mole) is 1:1.
4. (Original) A chemical entity according to claim 2 wherein the ratio of 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine to p-toluenesulfonic acid (by mole) is 1:1.
5. (Currently Amended) A chemical entity according to ~~any of claims 1 to 4~~ claim 1 in crystalline form.
6. (Currently Amended) A pharmaceutical composition comprising a chemical entity as claimed in ~~any of claims 1 to 5~~ claim 1 and a pharmaceutically acceptable carrier.

Claims 7 – 9 (Cancel).

10. (Currently Amended) A method of treatment of a psychotic disorder in mammals including humans, which comprises administering to a mammal in need thereof an effective amount of a chemical entity according to ~~any of claims 1 to 5~~ claim 1.
11. (New) A chemical entity according to claim 2 in crystalline form.
12. (New) A pharmaceutical composition comprising a chemical entity as claimed in claim 2 and a pharmaceutically acceptable carrier.
13. (New) A method of treatment of a psychotic disorder in mammals including humans, which comprises administering to a mammal in need thereof an effective amount of a chemical entity according to claim 2.